Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA)
2022-502021-18-00Phase 4Authorised
- Sponsor
- Queen Mary University of London
- Start
- Sep 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4 trial of sarilumab and etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: ACR-50 response at 12 weeks. Planned start Sep 2023; status: authorised.
02
Drugs
sarilumabetanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-502021-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502021-18-00.